BackSAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Overview

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Other Current Assets

Latest other current assets for BCYPU: $3.5M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$3.46M
3.72% YoYΔ $-133569.00 vs prior year quarter

Peer average / median

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Other Current Assets History

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) vs. peers: Other Current Assets Comparison

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) (BCYPU) FAQ

The latest other current assets for BCYPU is $3.5M as of June 2026. That compares with $3.6M in the prior-year period — down 3.7% year over year. Investors often review this figure alongside SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BCYPU's other current assets moved from $3.6M to $3.5M — a 3.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s operating scale or balance-sheet position.

A other current assets figure of $3.5M for BCYPU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BCYPU's other current assets ($3.5M), review year-over-year change from $3.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.